Hepatitis C virus-specific T-cell immune responses in seronegative injection drug users

M. Zeremski, M. A. Shu, Q. Brown, Y. Wu, Don Des Jarlais, M. P. Busch, A. H. Talal, B. R. Edlin

Research output: Contribution to journalArticle

Abstract

T-cell responses to hepatits C virus (HCV) antigens have been reported in high-risk HCV seronegative persons, suggesting that an effective cellular immune response might be able to clear infection without the development of antibodies. Such findings, however, could be explained by waning antibody or cross-reactivity to other antigens. To address these issues, we evaluated HCV-specific T-cell responses in 26 young (age 18-33 years) aviremic, seronegative injection drug users (IDUs) (median duration of injection, 6 years) by interferon-γ enzyme-linked immunospot (ELISpot) assay using 429 overlapping HCV peptides pooled in 21 mixes. Seventeen aviremic, seropositive IDUs (spontaneous resolvers) and 15 healthy people were used as positive and negative controls, respectively. The percentage of patients with HCV-specific cellular immune responses was similar in seronegative and seropositive aviremic IDUs (46%vs 59%, P = 0.4), while these responses were not detected in any of the negative controls. Among the seronegative IDUs, six (23%) had intermediate to very strong responses to 10-20 peptide mixes and another six (23%) had moderately strong responses for two to six mixes. The 12 seronegative IDUs with HCV-specific T-cell responses had higher demographical and behavioural risk profiles than the 14 IDUs without T-cell responses (estimated risk of HCV infection, 0.47 vs 0.26, P < 0.01). In conclusion, HCV-specific T-cell responses are common among high-risk, seronegative IDUs. The responses are broad and are associated with risk factors for HCV exposure, suggesting that they reflect true exposure to HCV in seronegative persons.

Original languageEnglish (US)
Pages (from-to)10-20
Number of pages11
JournalJournal of Viral Hepatitis
Volume16
Issue number1
DOIs
StatePublished - Jan 1 2009

Fingerprint

Drug Users
Hepacivirus
Viruses
T-Lymphocytes
Injections
Cellular Immunity
Enzyme-Linked Immunospot Assay
Antigens
Peptides
Antibodies
Virus Diseases
Interferons
Infection

Keywords

  • Cellular immunity
  • Elispot
  • Peptides

ASJC Scopus subject areas

  • Hepatology
  • Infectious Diseases
  • Virology

Cite this

Hepatitis C virus-specific T-cell immune responses in seronegative injection drug users. / Zeremski, M.; Shu, M. A.; Brown, Q.; Wu, Y.; Des Jarlais, Don; Busch, M. P.; Talal, A. H.; Edlin, B. R.

In: Journal of Viral Hepatitis, Vol. 16, No. 1, 01.01.2009, p. 10-20.

Research output: Contribution to journalArticle

Zeremski, M. ; Shu, M. A. ; Brown, Q. ; Wu, Y. ; Des Jarlais, Don ; Busch, M. P. ; Talal, A. H. ; Edlin, B. R. / Hepatitis C virus-specific T-cell immune responses in seronegative injection drug users. In: Journal of Viral Hepatitis. 2009 ; Vol. 16, No. 1. pp. 10-20.
@article{96089526f7c34d8a9acd4669bf67a7d3,
title = "Hepatitis C virus-specific T-cell immune responses in seronegative injection drug users",
abstract = "T-cell responses to hepatits C virus (HCV) antigens have been reported in high-risk HCV seronegative persons, suggesting that an effective cellular immune response might be able to clear infection without the development of antibodies. Such findings, however, could be explained by waning antibody or cross-reactivity to other antigens. To address these issues, we evaluated HCV-specific T-cell responses in 26 young (age 18-33 years) aviremic, seronegative injection drug users (IDUs) (median duration of injection, 6 years) by interferon-γ enzyme-linked immunospot (ELISpot) assay using 429 overlapping HCV peptides pooled in 21 mixes. Seventeen aviremic, seropositive IDUs (spontaneous resolvers) and 15 healthy people were used as positive and negative controls, respectively. The percentage of patients with HCV-specific cellular immune responses was similar in seronegative and seropositive aviremic IDUs (46{\%}vs 59{\%}, P = 0.4), while these responses were not detected in any of the negative controls. Among the seronegative IDUs, six (23{\%}) had intermediate to very strong responses to 10-20 peptide mixes and another six (23{\%}) had moderately strong responses for two to six mixes. The 12 seronegative IDUs with HCV-specific T-cell responses had higher demographical and behavioural risk profiles than the 14 IDUs without T-cell responses (estimated risk of HCV infection, 0.47 vs 0.26, P < 0.01). In conclusion, HCV-specific T-cell responses are common among high-risk, seronegative IDUs. The responses are broad and are associated with risk factors for HCV exposure, suggesting that they reflect true exposure to HCV in seronegative persons.",
keywords = "Cellular immunity, Elispot, Peptides",
author = "M. Zeremski and Shu, {M. A.} and Q. Brown and Y. Wu and {Des Jarlais}, Don and Busch, {M. P.} and Talal, {A. H.} and Edlin, {B. R.}",
year = "2009",
month = "1",
day = "1",
doi = "10.1111/j.1365-2893.2008.01016.x",
language = "English (US)",
volume = "16",
pages = "10--20",
journal = "Journal of Viral Hepatitis",
issn = "1352-0504",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Hepatitis C virus-specific T-cell immune responses in seronegative injection drug users

AU - Zeremski, M.

AU - Shu, M. A.

AU - Brown, Q.

AU - Wu, Y.

AU - Des Jarlais, Don

AU - Busch, M. P.

AU - Talal, A. H.

AU - Edlin, B. R.

PY - 2009/1/1

Y1 - 2009/1/1

N2 - T-cell responses to hepatits C virus (HCV) antigens have been reported in high-risk HCV seronegative persons, suggesting that an effective cellular immune response might be able to clear infection without the development of antibodies. Such findings, however, could be explained by waning antibody or cross-reactivity to other antigens. To address these issues, we evaluated HCV-specific T-cell responses in 26 young (age 18-33 years) aviremic, seronegative injection drug users (IDUs) (median duration of injection, 6 years) by interferon-γ enzyme-linked immunospot (ELISpot) assay using 429 overlapping HCV peptides pooled in 21 mixes. Seventeen aviremic, seropositive IDUs (spontaneous resolvers) and 15 healthy people were used as positive and negative controls, respectively. The percentage of patients with HCV-specific cellular immune responses was similar in seronegative and seropositive aviremic IDUs (46%vs 59%, P = 0.4), while these responses were not detected in any of the negative controls. Among the seronegative IDUs, six (23%) had intermediate to very strong responses to 10-20 peptide mixes and another six (23%) had moderately strong responses for two to six mixes. The 12 seronegative IDUs with HCV-specific T-cell responses had higher demographical and behavioural risk profiles than the 14 IDUs without T-cell responses (estimated risk of HCV infection, 0.47 vs 0.26, P < 0.01). In conclusion, HCV-specific T-cell responses are common among high-risk, seronegative IDUs. The responses are broad and are associated with risk factors for HCV exposure, suggesting that they reflect true exposure to HCV in seronegative persons.

AB - T-cell responses to hepatits C virus (HCV) antigens have been reported in high-risk HCV seronegative persons, suggesting that an effective cellular immune response might be able to clear infection without the development of antibodies. Such findings, however, could be explained by waning antibody or cross-reactivity to other antigens. To address these issues, we evaluated HCV-specific T-cell responses in 26 young (age 18-33 years) aviremic, seronegative injection drug users (IDUs) (median duration of injection, 6 years) by interferon-γ enzyme-linked immunospot (ELISpot) assay using 429 overlapping HCV peptides pooled in 21 mixes. Seventeen aviremic, seropositive IDUs (spontaneous resolvers) and 15 healthy people were used as positive and negative controls, respectively. The percentage of patients with HCV-specific cellular immune responses was similar in seronegative and seropositive aviremic IDUs (46%vs 59%, P = 0.4), while these responses were not detected in any of the negative controls. Among the seronegative IDUs, six (23%) had intermediate to very strong responses to 10-20 peptide mixes and another six (23%) had moderately strong responses for two to six mixes. The 12 seronegative IDUs with HCV-specific T-cell responses had higher demographical and behavioural risk profiles than the 14 IDUs without T-cell responses (estimated risk of HCV infection, 0.47 vs 0.26, P < 0.01). In conclusion, HCV-specific T-cell responses are common among high-risk, seronegative IDUs. The responses are broad and are associated with risk factors for HCV exposure, suggesting that they reflect true exposure to HCV in seronegative persons.

KW - Cellular immunity

KW - Elispot

KW - Peptides

UR - http://www.scopus.com/inward/record.url?scp=58149093118&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58149093118&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2893.2008.01016.x

DO - 10.1111/j.1365-2893.2008.01016.x

M3 - Article

VL - 16

SP - 10

EP - 20

JO - Journal of Viral Hepatitis

JF - Journal of Viral Hepatitis

SN - 1352-0504

IS - 1

ER -